Cargando…
First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate
BACKGROUND: The first wave of SARS-CoV-2 infection in Chile occurred during the cold season reaching a peak by the end of June 2020, with 80 % of the cases concentrated in its capital, Santiago. The main objective of this study was to estimate the attack rate during this first wave of SARS-CoV-2 in...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277990/ https://www.ncbi.nlm.nih.gov/pubmed/35872438 http://dx.doi.org/10.1016/j.epidem.2022.100606 |
_version_ | 1784746104136400896 |
---|---|
author | Vial, Pablo A. González, Claudia Apablaza, Mauricio Vial, Cecilia Lavín, M.Estela Araos, Rafael Rubilar, Paola Icaza, Gloria Florea, Andrei Pérez, Claudia Concha, Paula Bastías, Diego Errázuriz, María Paz Pérez, Ruth Guzmán, Francisco Olea, Andrea Guzmán, Eugenio Correa, Juan Munita, José Manuel Aguilera, Ximena |
author_facet | Vial, Pablo A. González, Claudia Apablaza, Mauricio Vial, Cecilia Lavín, M.Estela Araos, Rafael Rubilar, Paola Icaza, Gloria Florea, Andrei Pérez, Claudia Concha, Paula Bastías, Diego Errázuriz, María Paz Pérez, Ruth Guzmán, Francisco Olea, Andrea Guzmán, Eugenio Correa, Juan Munita, José Manuel Aguilera, Ximena |
author_sort | Vial, Pablo A. |
collection | PubMed |
description | BACKGROUND: The first wave of SARS-CoV-2 infection in Chile occurred during the cold season reaching a peak by the end of June 2020, with 80 % of the cases concentrated in its capital, Santiago. The main objective of this study was to estimate the attack rate during this first wave of SARS-CoV-2 in a large, densely populated city with more than seven million inhabitants. Since the number of confirmed cases provides biased information due to individuals' potential self-selection, mostly related to asymptomatic patients and testing access, we measured antibodies against SARS-CoV-2 to assess infection prevalence during the first wave in the city, as well as estimate asymptomatic cases, and infection fatality ratio. To our knowledge this is one of the few population-based cross-sectional serosurvey during the first wave in a highly affected emerging country. The challenges of pandemic response in urban settings in a capital city like Santiago, with heterogeneous subpopulations and high mobility through public transportation, highlight the necessity of more accurate information regarding the first waves of new emerging diseases. METHODS: From April 24 to June 21, 2020, 1326 individuals were sampled from a long-standing panel of household representatives of Santiago. Immunochromatographic assays were used to detect IgM and IgG antibody isotypes. RESULTS: Seroprevalence reached 6.79 % (95 %CI 5.58 %−8.26 %) in the first 107 days of the pandemic, without significant differences among sex and age groups; this figure indicates an attack rate 2.8 times higher than the one calculated with registered cases. It also changes the fatality rate estimates, from a 2.33 % case fatality rate reported by MOH to an estimated crude 1.00 % (CI95 % 0.97–1.03) infection fatality rate (adjusted for test performance 1.66 % [CI95 % 1.61–1.71]). Most seropositive were symptomatic (81,1 %). CONCLUSIONS: Despite the high number of cases registered, mortality rates, and the stress produced over the health system, the vast majority of the people remained susceptible to potential new epidemic waves. We contribute to the understanding of the initial spread of emerging epidemic threats. Consequently, our results provide better information to design early strategies that counterattack new health challenges in urban contexts. |
format | Online Article Text |
id | pubmed-9277990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92779902022-07-14 First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate Vial, Pablo A. González, Claudia Apablaza, Mauricio Vial, Cecilia Lavín, M.Estela Araos, Rafael Rubilar, Paola Icaza, Gloria Florea, Andrei Pérez, Claudia Concha, Paula Bastías, Diego Errázuriz, María Paz Pérez, Ruth Guzmán, Francisco Olea, Andrea Guzmán, Eugenio Correa, Juan Munita, José Manuel Aguilera, Ximena Epidemics Article BACKGROUND: The first wave of SARS-CoV-2 infection in Chile occurred during the cold season reaching a peak by the end of June 2020, with 80 % of the cases concentrated in its capital, Santiago. The main objective of this study was to estimate the attack rate during this first wave of SARS-CoV-2 in a large, densely populated city with more than seven million inhabitants. Since the number of confirmed cases provides biased information due to individuals' potential self-selection, mostly related to asymptomatic patients and testing access, we measured antibodies against SARS-CoV-2 to assess infection prevalence during the first wave in the city, as well as estimate asymptomatic cases, and infection fatality ratio. To our knowledge this is one of the few population-based cross-sectional serosurvey during the first wave in a highly affected emerging country. The challenges of pandemic response in urban settings in a capital city like Santiago, with heterogeneous subpopulations and high mobility through public transportation, highlight the necessity of more accurate information regarding the first waves of new emerging diseases. METHODS: From April 24 to June 21, 2020, 1326 individuals were sampled from a long-standing panel of household representatives of Santiago. Immunochromatographic assays were used to detect IgM and IgG antibody isotypes. RESULTS: Seroprevalence reached 6.79 % (95 %CI 5.58 %−8.26 %) in the first 107 days of the pandemic, without significant differences among sex and age groups; this figure indicates an attack rate 2.8 times higher than the one calculated with registered cases. It also changes the fatality rate estimates, from a 2.33 % case fatality rate reported by MOH to an estimated crude 1.00 % (CI95 % 0.97–1.03) infection fatality rate (adjusted for test performance 1.66 % [CI95 % 1.61–1.71]). Most seropositive were symptomatic (81,1 %). CONCLUSIONS: Despite the high number of cases registered, mortality rates, and the stress produced over the health system, the vast majority of the people remained susceptible to potential new epidemic waves. We contribute to the understanding of the initial spread of emerging epidemic threats. Consequently, our results provide better information to design early strategies that counterattack new health challenges in urban contexts. The Author(s). Published by Elsevier B.V. 2022-09 2022-07-13 /pmc/articles/PMC9277990/ /pubmed/35872438 http://dx.doi.org/10.1016/j.epidem.2022.100606 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Vial, Pablo A. González, Claudia Apablaza, Mauricio Vial, Cecilia Lavín, M.Estela Araos, Rafael Rubilar, Paola Icaza, Gloria Florea, Andrei Pérez, Claudia Concha, Paula Bastías, Diego Errázuriz, María Paz Pérez, Ruth Guzmán, Francisco Olea, Andrea Guzmán, Eugenio Correa, Juan Munita, José Manuel Aguilera, Ximena First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate |
title | First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate |
title_full | First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate |
title_fullStr | First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate |
title_full_unstemmed | First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate |
title_short | First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate |
title_sort | first wave of sars-cov-2 in santiago chile: seroprevalence, asymptomatic infection and infection fatality rate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277990/ https://www.ncbi.nlm.nih.gov/pubmed/35872438 http://dx.doi.org/10.1016/j.epidem.2022.100606 |
work_keys_str_mv | AT vialpabloa firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT gonzalezclaudia firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT apablazamauricio firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT vialcecilia firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT lavinmestela firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT araosrafael firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT rubilarpaola firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT icazagloria firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT floreaandrei firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT perezclaudia firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT conchapaula firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT bastiasdiego firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT errazurizmariapaz firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT perezruth firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT guzmanfrancisco firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT oleaandrea firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT guzmaneugenio firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT correajuan firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT munitajosemanuel firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate AT aguileraximena firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate |